Abstract:Chang Qi 1 &ast, Sheng-Wen Sun 2 &ast, Xian-Zhi Xiong 1 1 Department of Respiratory and Critical Care Medicine, NHC Key Laboratory of Pulmonary Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China; 2 Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xian-Zhi Xiong, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, People's Republic of China, Tel/Fax +86 27-85726705, Email Many studies have proved that the pathogenesis of the chronic obstructive pulmonary disease (COPD) and lung cancer is related, and may cause and affect each other to a certain extent. In fact, the change of chronic airway obstruction will continue to have an impact on the screening, treatment, and prognosis of lung cancer.In this comprehensive review, we outlined the links and heterogeneity between COPD and lung cancer and finds that factors such as gene expression and genetic susceptibility, epigenetics, smoking, epithelial mesenchymal transformation (EMT), chronic inflammation, and oxidative stress injury may all play a role in the process. Although the relationship between these two diseases have been largely determined, the methods to prevent lung cancer in COPD patients are still limited. Early diagnosis is still the key to a better prognosis. Thus, it is necessary to establish more intuitive screening evaluation criteria and find suitable biomarkers for lung cancer screening in high-risk populations with COPD. Some studies have indicated that COPD may change the efficacy of anti-tumor therapy by affecting the response of lung cancer patients to immune checkpoint inhibitors (ICIs). And for lung cancer patients with COPD, the standardized management of COPD can improve the prognosis. The treatment of lung cancer patients with COPD is an individualized, comprehensive, and precise process. The development of new targets and new strategies of molecular targeted therapy may be the breakthrough for disease treatment in the future. Graphical Keywords: COPD, lung cancer, endo-phenotyping of COPD, early diagnosis, biomarkers, immunotherapy Graphical Lung cancer has the highest case fatality rate of any tumor, according to a large number of data statistics, 1 and chronic obstructive pulmonary disease (COPD) is a common comorbidity of non small cell lung cancer (NSCLC). 2 In the 1980s, Skillrud and Tockman et al first proposed that the increasing incidence and mortality of lung cancer were related to the presence of airway obstruction and impairment of lung function. 3 A comprehensive analysis by the International Lung Cancer Federation demonstrated that COPD was independently associated with SCLC after adjustment for age, sex, and years of smoking. 4 Multifactor proportional risk analysis showed that patients with mild ventilatory dysfunction were more likely to suffer lung cancer than moderate and severe ventilatory dysfunction. Patients with moderate and severe ventilatory dysfunction were more likely to suffer lung cancer than persons with normal lung function. In addition, acute exacerbation of COPD, global initiative for chronic obstructive lung disease (GOLD) stage, and emphysema were also independent predictors of lung cancer, 5 among which GOLD I/II, older age, low BMI, and DLCO < 80% were more closely associated. 6 Lung cancer, in turn, is a significant factor in the morbidity and mortality of COPD. Zhang et al found that 50–70% of lung cancer patients demonstrated impaired lung function, especially those with squamous cell carcinoma with a higher probability of concomitant COPD in 2017. 7 Among many COPD, the high incidence rate of lung cancer is the highest, indicating that there may be a common mechanism and risk. In fact, many reviews have shown the relationship between COPD and lung cancer. However, due to the disease heterogeneity of COPD and lung cancer, the interaction and mechanism between chronic obstructive pulmonary disease and lung cancer are still controversial. Different from other relevant reviews, we expanded the scope of our study when discussing the association between COPD and lung cancer. The impact of COPD on lung cancer screening, prognosis, and anti-tumor treatment was focused on. In the long run, COPD is related to poor prognosis of lung cancer patients, but the special inflammatory environment of COPD may make lung cancer patients r -Abstract Truncated-

Interstitial lung abnormality in COPD is inversely associated with the comorbidity of lung cancer

Impact of Interstitial Lung Abnormalities on Disease Expression and Outcomes in COPD or Emphysema: A Systematic Review

Interstitial Lung Abnormality in COPD is Associated with Higher Prevalence of Antinuclear Antibody.

Prognostic impact of interstitial lung abnormalities in lung cancer: a systematic review and meta-analysis

Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis

Clinical Outcomes and Risk Factor of Immune Checkpoint Inhibitors-Related Pneumonitis in Non-Small Cell Lung Cancer Patients with Chronic Obstructive Pulmonary Disease

Interstitial Lung Abnormalities in Patients With Locally Advanced Esophageal Cancer: Prevalence, Risk Factors, and Clinical Implications

The Diagnostic Value of Systemic Immune-Inflammatory Index (SII) and Lymphocyte–Albumin–Neutrophil Ratio (LANR) in Chronic Obstructive Pulmonary Disease with Lung Cancer

Clinical analysis of 21 patients with interstitial lung disease complicated with lung cancer

Clinical and genomic characteristics of lung cancer concomitant chronic obstructive pulmonary disease (COPD).

Associations between chronic obstructive pulmonary disease and ten common cancers: novel insights from Mendelian randomization analyses

Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors

Status of Coexisting Chronic Obstructive Pulmonary Disease and Its Clinicopathological Features in Patients Undergoing Lung Cancer Surgery: a Cross-Sectional Study of 3,006 Cases.

From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis

Is There a Link between Chronic Obstructive Pulmonary Disease and Lung Adenocarcinoma? A Clinico-Pathological and Molecular Study

Malignancies in Patients with Interstitial Lung Diseases: A Single Center Observational Study

Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China

Comorbidity in Lung Cancer Patients and Its Association with Hospital Readmission and Fatality in China

Clinical outcomes of interstitial lung abnormalities: a systematic review and meta-analysis

Bronchial epithelial gene expression and interstitial lung abnormalities

Lung Cancer and Interstitial Lung Diseases